07/02/2016 23:08:50 1-888-992-3836 (toll free) Free Membership Login

Neurocrine Biosciences News (NASDAQ:NBIX)

DateTimeSource
Headline
02/03/20161:00PMPRNUSNeurocrine Biosciences to Present at the Leerink Partners 5th Annual Global Healthcare Conference
Neurocrine Biosciences to Present at the Leerink Partners 5th Annual Global Healthcare Conference Live Audio Webcast will be on February 10, 2016 PR Newswire SAN DIEGO, Feb. 3, 2016 SAN DIEGO, Feb. 3, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and CEO... More...>>
02/02/20168:30AMPRNUSNeurocrine Announces Initiation of Phase II Clinical Study of VMAT2 Inhibitor Valbenazine in Children and Adolescents with To...
Neurocrine Announces Initiation of Phase II Clinical Study of VMAT2 Inhibitor Valbenazine in Children and Adolescents with Tourette Syndrome Six-Week T-Force GREEN Study to Assess the Safety, Tolerability and Efficacy of Valbenazine in 90 Pediatric Subjects PR Newswire SAN DIEGO, Feb. 2, 2016 SAN DIEGO, Feb. 2, 2016 /PRNewswire/... More...>>
01/28/20166:55AMPRNUSAbbVie Initiates Enrollment in Phase 3 Clinical Program for Elagolix in Patients with Uterine Fibroids
AbbVie Initiates Enrollment in Phase 3 Clinical Program for Elagolix in Patients with Uterine Fibroids - The Elagolix Phase 3 uterine fibroid clinical development program includes two replicate, pivotal, six-month efficacy and safety studies followed by a six-month safety and efficacy extension study. - Primary endpoint... More...>>
01/04/20162:00PMPRNUSNeurocrine Biosciences to Present at the 34th Annual J.P. Morgan Healthcare Conference
Neurocrine Biosciences to Present at the 34th Annual J.P. Morgan Healthcare Conference Live Audio Webcast will be on January 11, 2016 PR Newswire SAN DIEGO, Jan. 4, 2016 SAN DIEGO, Jan. 4, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer... More...>>
12/16/20154:05PMPRNUSNeurocrine Announces Successful Completion of Phase Ib T-Force Study of VMAT2 Inhibitor NBI-98854 in Adolescents and Children...
Neurocrine Announces Successful Completion of Phase Ib T-Force Study of VMAT2 Inhibitor NBI-98854 in Adolescents and Children with Tourette Syndrome Once-Daily Valbenazine was Safe and Well Tolerated with a 31% Reduction from Baseline in Tourette Symptoms after Two Weeks of Treatment Phase II Study in Children and Adolescents... More...>>
11/25/20151:00PMPRNUSNeurocrine Biosciences to Present at the 27th Annual Piper Jaffray Healthcare Conference
Neurocrine Biosciences to Present at the 27th Annual Piper Jaffray Healthcare Conference Live Audio Webcast will be on December 2, 2015 PR Newswire SAN DIEGO, Nov. 25, 2015 SAN DIEGO, Nov. 25, 2015 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and CEO of Neurocrine... More...>>
11/11/20152:10PMPRNUSNeurocrine Biosciences to Present at the Jefferies Autumn 2015 Global Healthcare Conference
Neurocrine Biosciences to Present at the Jefferies Autumn 2015 Global Healthcare Conference Live Audio Webcast will be on November 18, 2015 PR Newswire SAN DIEGO, Nov. 11, 2015 SAN DIEGO, Nov. 11, 2015 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and CEO of Neurocrine... More...>>
11/04/20153:30PMPRNUSNeurocrine Biosciences to Present at Credit Suisse's 24th Annual Healthcare Conference
Neurocrine Biosciences to Present at Credit Suisse's 24th Annual Healthcare Conference Live Audio Webcast will be on November 11, 2015 PR Newswire SAN DIEGO, Nov. 4, 2015 SAN DIEGO, Nov. 4, 2015 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and CEO of Neurocrine... More...>>
11/04/20158:00AMPRNUSNeurocrine Biosciences Announces Expansion of its Clinical Pipeline
Neurocrine Biosciences Announces Expansion of its Clinical Pipeline New Molecular Entity for Essential Tremor Enters Phase I Clinical Investigation PR Newswire SAN DIEGO, Nov. 4, 2015 SAN DIEGO, Nov. 4, 2015 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX), a biotechnology company focused on neurological and... More...>>
10/29/20154:01PMPRNUSNeurocrine Biosciences Reports Third Quarter 2015 Results
Neurocrine Biosciences Reports Third Quarter 2015 Results NBI-98854 Positive in Phase III Study in Tardive Dyskinesia, NDA filing in 2016 Elagolix Phase IIb Study in Uterine Fibroids is Positive, Moving into Phase III Development PR Newswire SAN DIEGO, Oct. 29, 2015 SAN DIEGO, Oct. 29, 2015 /PRNewswire/ -- Neurocrine... More...>>
10/22/20151:00PMPRNUSNeurocrine Biosciences Announces Conference Call and Webcast to Report Third Quarter 2015 Results
Neurocrine Biosciences Announces Conference Call and Webcast to Report Third Quarter 2015 Results Conference Call and Webcast Scheduled For Thursday, October 29, 2015 PR Newswire SAN DIEGO, Oct. 22, 2015 SAN DIEGO, Oct. 22, 2015 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company... More...>>
10/20/20158:30AMPRNUSNeurocrine Announces Initiation of Phase II Clinical Study of VMAT2 Inhibitor NBI-98854 in Adults with Tourette Syndrome
Neurocrine Announces Initiation of Phase II Clinical Study of VMAT2 Inhibitor NBI-98854 in Adults with Tourette Syndrome Eight Week Study to Assess the Safety, Tolerability and Efficacy of Valbenazine in 90 Adult Subjects PR Newswire SAN DIEGO, Oct. 20, 2015 SAN DIEGO, Oct. 20, 2015 /PRNewswire/ -- Neurocrine Biosciences... More...>>
10/08/20156:30AMPRNUSNeurocrine Announces Positive Results from Phase III Kinect 3 Study of NBI-98854 in Tardive Dyskinesia
Neurocrine Announces Positive Results from Phase III Kinect 3 Study of NBI-98854 in Tardive Dyskinesia Study Meets Primary Endpoint, Submission of New Drug Application Planned for 2016 Company to Host Conference Call and Webcast Thursday, October 8th at 8:00 AM EDT/ 5:00 AM PDT PR Newswire SAN DIEGO, Oct. 8, 2015 SAN DIEGO... More...>>
09/30/20154:30PMPRNUSNeurocrine Biosciences Announces the Appointment of George J. Morrow to its Board of Directors
Neurocrine Biosciences Announces the Appointment of George J. Morrow to its Board of Directors PR Newswire SAN DIEGO, Sept. 30, 2015 SAN DIEGO, Sept. 30, 2015 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it has appointed George J. Morrow to its Board of Directors. Mr. Morrow has over... More...>>
09/16/20159:00AMPRNUSAbbVie Announces Plans to Proceed to Phase 3 Evaluation of Elagolix in Patients with Uterine Fibroids
AbbVie Announces Plans to Proceed to Phase 3 Evaluation of Elagolix in Patients with Uterine Fibroids PR Newswire NORTH CHICAGO, Illinois, Sept. 16, 2015 - Results from six-month, Phase 2b safety and efficacy trial show elagolix met composite primary efficacy endpoint - Phase 3 program is targeted to begin the first quarter... More...>>
09/16/20159:00AMPRNUSAbbVie Announces Plans to Proceed to Phase 3 Evaluation of Elagolix in Patients with Uterine Fibroids
AbbVie Announces Plans to Proceed to Phase 3 Evaluation of Elagolix in Patients with Uterine Fibroids - Results from six-month, Phase 2b safety and efficacy trial show elagolix met composite primary efficacy endpoint - Phase 3 program is targeted to begin the first quarter of 2016 PR Newswire NORTH CHICAGO, Ill., Sept... More...>>
09/10/20152:12PMPRNUS/C O R R E C T I O N -- Neurocrine Biosciences, Inc./
/C O R R E C T I O N -- Neurocrine Biosciences, Inc./ PR Newswire SAN DIEGO, Sept. 10, 2015 In the news release, Neurocrine Biosciences to Present at the Morgan Stanley Global Healthcare Conference, issued 10-Sep-2015 by Neurocrine Biosciences, Inc. over PR Newswire, the first paragraph, first sentence, should read "President"... More...>>
09/10/20151:00PMPRNUSNeurocrine Biosciences to Present at the Morgan Stanley Global Healthcare Conference
Neurocrine Biosciences to Present at the Morgan Stanley Global Healthcare Conference Live Audio Webcast Will be on September 17, 2015 PR Newswire SAN DIEGO, Sept. 10, 2015 SAN DIEGO, Sept. 10, 2015 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, resident and CEO of Neurocrine... More...>>
09/03/20158:30AMPRNUSNeurocrine Biosciences Announces the Appointment of Dr. Alfred W. Sandrock to its Board of Directors
Neurocrine Biosciences Announces the Appointment of Dr. Alfred W. Sandrock to its Board of Directors PR Newswire SAN DIEGO, Sept. 3, 2015 SAN DIEGO, Sept. 3, 2015 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it has appointed Alfred W. Sandrock, Jr., M.D., Ph.D. to its Board of Directors... More...>>
09/02/20151:00PMPRNUSNeurocrine Biosciences to Present at the Baird 2015 Healthcare Conference
Neurocrine Biosciences to Present at the Baird 2015 Healthcare Conference Live Audio Webcast Will be on September 9, 2015 PR Newswire SAN DIEGO, Sept. 2, 2015 SAN DIEGO, Sept. 2, 2015 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Tim Coughlin, Chief Financial Officer of Neurocrine Biosciences... More...>>


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:34 V:us D:20160208 04:08:51